6/30/23, 12:47 AM WOSCOPS Pathway Feedback Search Clinical Topics Home Studies WOSCOPS WOSCOPS Disease Dyslipidemia Trial question What is the role of pravastatin therapy in male patients with hypercholesterolemia and no history of MI? Study design Multi-center Double blinded RCT Population 6595 male patients Inclusion criteria: male patients (45-64 years of age) with hypercholesterolemia and no history of MI Key exclusion criteria: serious ECG abnormalities or arrhythmia such as AF; history of myocardial infarction or other serious illness, or hospitalization for stable angina within the previous 12 months Interventions N=3302 pravastatin (40 mg each evening) N=3293 placebo (matching placebo each evening) Primary outcome Nonfatal MI or death from CHD 7.9 % 7.9 5.9 % 5.5 4.0 % Significant decrease 2.0 % NNT = 42 0.0 % Pravastatin Placebo https://web.pathway.md/studies/rec51ZFuxrG2dQQAy 1/2 6/30/23, 12:47 AM WOSCOPS Pathway Significant decrease in nonfatal MI or death from CHD (5.5% vs. 7.9%; RR 0.69, 95% CI 0.57 to 0.83) Secondary outcomes Significant decrease in definite nonfatal MI (4.6% vs. 6.5%; RR 0.69, 95% CI 0.55 to 0.85) Safety outcomes No significant differences in deaths from non-cardiovascular causes (56 vs. 62, p=0.54), strokes (46 vs. 51), or incident cancers (116 vs. 106, p=0.55). Conclusion In male patients (45-64 years of age) with hypercholesterolemia and no history of MI, pravastatin was superior to placebo with respect to nonfatal MI or death from CHD. Reference Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301-7. Open reference URL https://web.pathway.md/studies/rec51ZFuxrG2dQQAy 2/2